OBJECTIVE Acellular pertussis vaccines were introduced with the promise of an improved safety profile compared with whole-cell vaccines. In 1997-1998, Canada adopted 1 combination acellular pertussis vaccine, having previously used 1 particular combination whole-cell pertussis vaccine. We hypothesized that the change would result in a decrease in hospitalization rates for seizures and reports o...

bordetella pertussis is a gram negative bacterium that causes respiratory tract infection in human (whooping cough). pertussis toxin (pt) is the main component of current acellular pertussis vaccine and the s1 (subunit1) is the main immunogenic part of it. thus, s1 has been the target of many studies as a potent candidate of acellular vaccine against bordetella pertussis, lacking the side effec...

OBJECTIVE To evaluate the safety of infant immunization with acellular pertussis vaccines in the United States. BACKGROUND The US Food and Drug Administration approved the first acellular pertussis vaccine for use in infants in the United States on July 31, 1996. OUTCOME MEASURES Adverse events in the United States after infant immunization with pertussis-containing vaccines, representing t...

The availability of acellular pertussis vaccines, which appear to be both safe and immunogenic in adults, will require that vaccine advisory groups make recommendations regarding their use. Pertussis in adults has negligible mortality but is responsible for about one-quarter of cases of chronic cough syndrome in young adults. Parents and other infant caregivers are important transmitters of per...

Using a murine respiratory infection model, we have demonstrated previously that infection with Bordetella pertussis or immunization with a whole-cell pertussis vaccine induced antigen-specific Th1 cells, which conferred a high level of protection against aerosol challenge. In contrast, immunization with an acellular vaccine, consisting of the B. pertussis components detoxified pertussis toxin,...

a purification procedure of pertussis toxin (pt) from submerged culture of bordetella pertussis (b.pertussis) strain 134 using adsorption and affinity chromatography was discussed. the yield of the resulting pt was approximately 37.5mg/l of concentrated culture supernatant. the polypeptide pattern of the purified pt was investigated by sds-page and showed five bands between 11 to 26 kda using l...

OBJECTIVES The purpose of this work was to evaluate the long-term effectiveness of vaccination with acellular pertussis vaccines at 3, 5, and 12 months of age. METHODS Clinical follow-up of reported culture- and polymerase chain reaction-confirmed cases of pertussis was initiated during October 1997 in most of Sweden (except Gothenburg and environs). The study population included 90% of Swedi...

BACKGROUND A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the effectiveness of the pertussis vaccine and characterize the effect of waning immunity and whole-cell vaccine priming. METHODS We used the test-negative design, a nested case-control study with test-negative individuals ...

BACKGROUND Vaccine development has largely focused on the ability of vaccines to reduce disease in individual hosts, with less attention to assessing the vaccine's effects on transmission between hosts. Current acellular vaccines against Bordetella pertussis are effective in preventing severe disease but have little effect on less severe coughing illness that can mediate transmission. METHODS...

BACKGROUND Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all ac...